skip to main content

News Archive

Date: 04/28/2022
The University of Michigan Rogel Cancer Center will provide funding support to 12 exceptional faculty researchers, 2 early career clinical researchers and six medical and graduate students. In addition, the center has launched a new program for Rogel Scholars in Cancer Health Equity, to support two faculty members who are working to address the cancer burden in historically underserved or excluded populations.
Date: 04/25/2022
By using an artificial intelligence-based system, researchers improved doctors' assessment of whether patients with bladder cancer had a complete response to chemotherapy before undergoing a radical cystectomy (bladder cancer removal surgery).
Date: 04/20/2022
Noninvasive sound technology developed at the University of Michigan breaks down liver tumors in rats, kills cancer cells and spurs the immune system to prevent further spread—an advance that could lead to improved cancer outcomes in humans.
Date: 04/20/2022
The Emerging Leaders Council (ELC) is comprised of 15 early career faculty members interested in taking a larger role in the cancer center. Candidates are selected by the SLC and serve 3-year terms. The council is led by a chair, and two co-chairs elected by the ELC members to serve one-year terms.
Date: 04/12/2022
A team at the University of Michigan Health Rogel Cancer Center, in partnership with the statewide Michigan Radiation Oncology Quality Consortium, or MROQC, lung cancer collaborative, co-led by Shruti Jolly, M.D., and Peter Paximadis, M.D., of Spectrum Health Lakeland in St. Joseph, Michigan, found that raising awareness about the risk of radiation exposure to the heart and standardizing cardiac exposure limits reduced the average dose to the heart by 15% and reduced the number of patients receiving the highest heart doses by half without minimizing tumor treatment or increasing dosage to other at-risk organs in the chest.
Date: 03/29/2022
More than 40 Rogel Cancer Center-led research efforts will be presented during the AACR Annual Meeting 2022, which runs April 8-13 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online.
Date: 03/28/2022
Treatment for glioma has long relied on MRI imaging to track tumor markers and treatment response. But findings from a team at the University of Michigan Rogel Cancer Center, led by Carl Koschmann, M.D., pediatric neuro-oncologist at University of Michigan Health C.S. Mott Children’s Hospital and researcher with the Chad Carr Pediatric Brain Tumor Center, suggest a new method could provide additional data about tumor markers before changes appear on an MRI, indicating possible strategies to help clinicians address this aggressive form of cancer.
Date: 03/14/2022
A new clinical trial from a team at the University of Michigan Rogel Cancer Center uses innovative basic science research methods to offer hope and a new treatment to glioblastoma patients. A collaborative team of Rogel physicians, led by Daniel Wahl, M.D., Ph.D., hopes that grounding their trial in rigorous and innovative biology from the very beginning will help this approach succeed where so many other potential glioblastoma treatments have failed.
Date: 03/14/2022
Meet Madison McTevia, M.A., C.C.L.S., clinical specialist and program coordinator for the Families Facing Cancer program at the Rogel Cancer Center. And, meet Kevin (or "Kev" as he affectionally known) her 210-pound potbelly pig.
Date: 03/11/2022
Paul Swiecicki, M.D., has been named medical director for the Clinical Research Specimen Processing (CRSP) laboratory at the U-M Rogel Cancer Center. Swiecicki, along with lab manager Keri Innes, will oversee the lab's expansion into an additional space on the Rogel building's 7th floor to accommodate an increasing workload. The laboratory is responsible for managing bio-specimens for all clinical oncology trials in progress at Rogel Cancer Center.